Skip to content
‹ Back to IndustriesSciences

Overcoming Problems with Hybrid Rocket Engines is Key to Launching Us Further into Space

Hybrid rocket engines combine elements of both liquid and solid propulsion systems to offer improved efficiency, safety, and control compared to traditional rocket technologies. Advances in hybrid propulsion are seen as a key enabler for more accessible and cost-effective space exploration. Greater accessibility to space could accelerate scientific discovery and technological innovation.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · HybridRobert FabianRocket EnginesSpace
Share

Key takeaways

01

Hybrid rocket engines offer a middle ground between liquid and solid propulsion, providing better control and safety.

02

Improved rocket technology lowers barriers to space exploration for commercial and scientific missions.

03

Ongoing development of hybrid engines could unlock new opportunities for deep space travel and research.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Hybrid isn’t just the word with us earthlings, it’s also the next big thing in space technology. Hybrid rocket engines have been developed to increase efficiency and control over more established liquid and solid rocket engines. With better rocket technology comes more accessible space exploration, meaning the potential for scientific discoveries and technological advancements grows exponentially. In fact, according to a report by Morgan Stanley, the global space industry could be worth $1.1 trillion or more by 2040.

Still, while hybrid rockets offer certain advantages over the more traditional rockets, they also come with several drawbacks, including the fact that refueling hybrid rockets is more challenging than refueling liquid and solid rockets. Large hybrid orbital rockets also require turbopumps, but turbopumps can’t use the same fuel and oxidizer as in liquid-propellant rockets. Finally, there hasn’t been as much research on hybrid rockets as with other rockets, so many of their problems have not been fully addressed.

Private aerospace company Vaya Space has been making waves in the industry with its revolutionary Vortex hybrid engine technology. Robert Fabian, the company’s Chief Operating Officer, offers deeper insights into this new technology and its potential impact on space travel.

Robert’s Thoughts:

“What makes Vaya Space unique really is our engine technology, what we call the Vortex hybrid engine. We’ve taken the historical problems of hybrid engines and core performance and combustion instability and solved them, producing an engine that’s significantly cheaper, significantly simpler, and significantly safer than anything else out there on the market.

When I first heard about this technology, I didn’t believe it. I had to do the math myself to make sure it would work, and I’ve watched it go from math on a page and a concept to lab scale tests, to larger engine tests, to flight tests, and I’m really looking forward to seeing the production engine for our Dauntless launch vehicle fire for the first time.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Crown Bioscience Appoints Guy Sheets as Senior Vice President, Commercial

Crown Bioscience appointed Guy Sheets as Senior Vice President, Commercial, bringing over 30 years of pharma and life sciences experience to lead the CRO's global commercial strategy. Sheets previously held senior commercial roles at QPS Holdings, CenExel, SGS Health Sciences, Lonza, and Thermo Fisher Scientific.

  • 01Guy Sheets brings 30+ years of commercial leadership across pharma, biotech, and life sciences, most recently as VP, Head of Global Business Development at QPS Holdings
  • 02Crown Bioscience operates 9 facilities across the US, Europe, and APAC with a portfolio of 2,800+ patient-derived xenograft models and 1,000+ tumor organoid models across 35 cancer indications
  • 03Sheets will lead Crown Bioscience’s global commercial strategy to drive growth, expand market presence, and strengthen client partnerships

Nov 3, 2026

Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Merck's €300 million Korean plant brings biologics supplies closer to Asia-Pacific drugmakers

Merck has invested more than €300 million in a new bioprocessing production center in Daejeon, South Korea. It is the largest life science investment Merck has made in the region to date. The 44,500-square-meter facility makes cell culture media, process liquids and sterile sampling products to support biologics manufacturing from development through commercial supply.

  • 01A single Asia-Pacific site now supplies both small custom pre-GMP media and commercial-scale media, so a regional biologics program could scale without switching to a source outside the region.
  • 02Daejeon supplies cell culture media, process liquids, ready-to-use cleaning-in-place solutions and sterile sampling products.
  • 03The useful supplier question has moved past whether Merck has an Asia-Pacific plant: ask which product lines ship from Daejeon and what batch traceability data customers can see.

Nov 3, 2026

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox sees replacements driving a third of quantum cascade laser shipments by 2030

IndexBox projects the quantum cascade laser market to grow 8% to 12% a year through 2035, linking the outlook to faster adoption of mid-infrared spectroscopy in process control, environmental monitoring and pharmaceutical QA. It says QCLs win on high spectral brightness and room-temperature operation in compact form factors, and that the installed base of analytical instruments is growing.

  • 01Roughly one in three quantum cascade lasers shipped in 2030 is projected to replace equipment already in service, so maintenance calendars will set a growing share of demand.
  • 02For a plant or QA lab running QCL-based analyzers, the useful question is which laser maker sits inside each instrument and whether a second source exists.
  • 03Analyzers bought on a three-to-five-year cycle in 2026 come due between 2029 and 2031. Those years will show whether the forecast replacement wave turns up in real orders.

Oct 26, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512